Intellia Therapeutics Inc
NTLA: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$56.00 | Fblt | Plbmkpwbf |
Intellia’s Pipeline Continues to Make Progress; Maintaining $85 FVE, Shares Very Undervalued
Intellia reported third-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. We maintain our positive outlook and fair value estimate of $85 per share. We view the stock as very undervalued, currently trading in 4-star territory. Collaboration revenue totaled $13 million for the quarter, which was primarily driven by Intellia’s collaborations with AvenCell and Kyverna.